About the Company
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Editas Medicine, Inc.
Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch
Editas Medicine Inc. (EDIT) has disclosed a new risk, in the Regulation category. Editas Medicine Inc. faces significant ...
Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript
Editas Medicine, Inc. (NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - Chief ...
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ: EDIT) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei ...
Editas Medicine, Inc. (NASDAQ:EDIT) Reported Earnings Last Week And ...
Editas Medicine, Inc. (NASDAQ:EDIT) just released its latest full-year results and things are looking bullish. Revenues of US$78m beat estimates by a substantial 177% margin.
Editas Medicine, Inc. Just Reported A Surprise Profit And ... - Nasdaq
Editas Medicine, Inc. (NASDAQ:EDIT) came out with its third-quarter results last week, and we wanted to see how the business is performing and what industry forecasters think of the company ...
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ: EDIT) Q4 2023 Earnings Call Transcript February 28, 2024 Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas ...
CAMBRIDGE, Mass., and DEVENS, Mass., July 27, 2023 /PRNewswire/ -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur ...
Editas Medicine, Inc. (NASDAQ:EDIT) insiders placed bullish bets worth ...
Insiders own 1.4% of Editas Medicine shares, worth about US$35m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management ...
Editas Medicine Announces Third Quarter 2023 Results and Business ...
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and ...
Vertex to pay Editas up to $100M, plus hefty annual fee, for CRISPR ...
Vertex Pharmaceuticals Inc. will pay up to $100M to a local competitor before it starts selling its newly approved CRISPR sickle-cell treatment. The agreement comes after a drawn-out patent battle ...
Editas Medicine tumbles more than 6% after announcing job cuts ...
Editas Medicine Inc. [s: edit] is cutting approximately 20% of its workforce. The company reported 264 full-time employees as of Feb. 1, 2022, according to its annual report.
Similar Companies
Loading the latest forecasts...